New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:03 EDTOREXBlue Chip says Orexigen accelerating patient enrollment for The Light Study
Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, said it has partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigenís cardiovascular outcomes trial evaluating Contrave, an investigational medication being evaluated for the treatment of obesity. Approximately 9,000 patients will be randomized in the study within the next few weeks, nearly 14 months ahead of original forecasts, Blue Chip said.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:28 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
07:21 EDTOREXOrexigen Mysimba receives positive CHMP opinion
Subscribe for More Information
07:20 EDTOREXOrexigen weight loss drug recommended in Europe
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting a marketing authorization for Mysimba for weight management of overweight or obese adults. The medicine is recommended for use in addition to a reduced-calorie diet and physical activity. Mysimba is made by Orexigen.
December 15, 2014
10:10 EDTOREXHigh option volume stocks:
High option volume stocks: RVBD AGCO FRO CRUS UBNT LH PAY PETM OREX KOS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use